These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32532817)

  • 1. T cell receptor interactions with human leukocyte antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4.
    Coles CH; McMurran C; Lloyd A; Hock M; Hibbert L; Raman MCC; Hayes C; Lupardus P; Cole DK; Harper S
    J Biol Chem; 2020 Aug; 295(33):11486-11494. PubMed ID: 32532817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy.
    Simister PC; Border EC; Vieira JF; Pumphrey NJ
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
    Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes.
    Smith SN; Sommermeyer D; Piepenbrink KH; Blevins SJ; Bernhard H; Uckert W; Baker BM; Kranz DM
    J Mol Biol; 2013 Nov; 425(22):4496-507. PubMed ID: 23954306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
    Chinnasamy N; Wargo JA; Yu Z; Rao M; Frankel TL; Riley JP; Hong JJ; Parkhurst MR; Feldman SA; Schrump DS; Restifo NP; Robbins PF; Rosenberg SA; Morgan RA
    J Immunol; 2011 Jan; 186(2):685-96. PubMed ID: 21149604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for ineffective T-cell responses to MHC anchor residue-improved "heteroclitic" peptides.
    Madura F; Rizkallah PJ; Holland CJ; Fuller A; Bulek A; Godkin AJ; Schauenburg AJ; Cole DK; Sewell AK
    Eur J Immunol; 2015 Feb; 45(2):584-91. PubMed ID: 25471691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA.
    Holland CJ; Crean RM; Pentier JM; de Wet B; Lloyd A; Srikannathasan V; Lissin N; Lloyd KA; Blicher TH; Conroy PJ; Hock M; Pengelly RJ; Spinner TE; Cameron B; Potter EA; Jeyanthan A; Molloy PE; Sami M; Aleksic M; Liddy N; Robinson RA; Harper S; Lepore M; Pudney CR; van der Kamp MW; Rizkallah PJ; Jakobsen BK; Vuidepot A; Cole DK
    J Clin Invest; 2020 May; 130(5):2673-2688. PubMed ID: 32310221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice.
    Shirakura Y; Mizuno Y; Wang L; Imai N; Amaike C; Sato E; Ito M; Nukaya I; Mineno J; Takesako K; Ikeda H; Shiku H
    Cancer Sci; 2012 Jan; 103(1):17-25. PubMed ID: 21951605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.
    Wieckowski S; Baumgaertner P; Corthesy P; Voelter V; Romero P; Speiser DE; Rufer N
    J Immunol; 2009 Oct; 183(8):5397-406. PubMed ID: 19786555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-resolution structure of HLA-A*0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene.
    Hillig RC; Coulie PG; Stroobant V; Saenger W; Ziegler A; Hülsmeyer M
    J Mol Biol; 2001 Jul; 310(5):1167-76. PubMed ID: 11502003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and structural basis for selection of a ubiquitous T cell receptor deployed in Epstein-Barr virus infection.
    Miles JJ; Bulek AM; Cole DK; Gostick E; Schauenburg AJ; Dolton G; Venturi V; Davenport MP; Tan MP; Burrows SR; Wooldridge L; Price DA; Rizkallah PJ; Sewell AK
    PLoS Pathog; 2010 Nov; 6(11):e1001198. PubMed ID: 21124993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retargeting of a T cell line by anti MAGE-3/HLA-A2 alpha beta TCR gene transfer.
    Calogero A; Hospers GA; Krüse KM; Schrier PI; Mulder NH; Hooijberg E; de Leij LF
    Anticancer Res; 2000; 20(3A):1793-9. PubMed ID: 10928109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
    Cameron BJ; Gerry AB; Dukes J; Harper JV; Kannan V; Bianchi FC; Grand F; Brewer JE; Gupta M; Plesa G; Bossi G; Vuidepot A; Powlesland AS; Legg A; Adams KJ; Bennett AD; Pumphrey NJ; Williams DD; Binder-Scholl G; Kulikovskaya I; Levine BL; Riley JL; Varela-Rohena A; Stadtmauer EA; Rapoport AP; Linette GP; June CH; Hassan NJ; Kalos M; Jakobsen BK
    Sci Transl Med; 2013 Aug; 5(197):197ra103. PubMed ID: 23926201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing the Conformational Dynamics of Affinity-Enhanced T Cell Receptor Variants upon Binding the Peptide-Bound Major Histocompatibility Complex by Hydrogen/Deuterium Exchange Mass Spectrometry.
    Merkle PS; Trabjerg E; Hongjian S; Ferber M; Cuendet MA; Jørgensen TJD; Luescher I; Irving M; Zoete V; Michielin O; Rand KD
    Biochemistry; 2021 Mar; 60(11):859-872. PubMed ID: 33689297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structurally silent peptide anchor modifications allosterically modulate T cell recognition in a receptor-dependent manner.
    Smith AR; Alonso JA; Ayres CM; Singh NK; Hellman LM; Baker BM
    Proc Natl Acad Sci U S A; 2021 Jan; 118(4):. PubMed ID: 33468649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and kinetic basis for heightened immunogenicity of T cell vaccines.
    Chen JL; Stewart-Jones G; Bossi G; Lissin NM; Wooldridge L; Choi EM; Held G; Dunbar PR; Esnouf RM; Sami M; Boulter JM; Rizkallah P; Renner C; Sewell A; van der Merwe PA; Jakobsen BK; Griffiths G; Jones EY; Cerundolo V
    J Exp Med; 2005 Apr; 201(8):1243-55. PubMed ID: 15837811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
    Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A major histocompatibility complex-peptide-restricted antibody and t cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with FAB-HYB3.
    Hülsmeyer M; Chames P; Hillig RC; Stanfield RL; Held G; Coulie PG; Alings C; Wille G; Saenger W; Uchanska-Ziegler B; Hoogenboom HR; Ziegler A
    J Biol Chem; 2005 Jan; 280(4):2972-80. PubMed ID: 15537658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.
    Borbulevych OY; Insaidoo FK; Baxter TK; Powell DJ; Johnson LA; Restifo NP; Baker BM
    J Mol Biol; 2007 Oct; 372(5):1123-36. PubMed ID: 17719062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of relationships between peptide/MHC structural features and naive T cell frequency in humans.
    Reiser JB; Legoux F; Gras S; Trudel E; Chouquet A; Léger A; Le Gorrec M; Machillot P; Bonneville M; Saulquin X; Housset D
    J Immunol; 2014 Dec; 193(12):5816-26. PubMed ID: 25392532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.